node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
ABCC4 | HPGD | ENSP00000494609 | ENSP00000296522 | Multidrug resistance-associated protein 4; May be an organic anion pump relevant to cellular detoxification; Belongs to the ABC transporter superfamily. ABCC family. Conjugate transporter (TC 3.A.1.208) subfamily. | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | 0.424 |
ABCC4 | SLCO2A1 | ENSP00000494609 | ENSP00000311291 | Multidrug resistance-associated protein 4; May be an organic anion pump relevant to cellular detoxification; Belongs to the ABC transporter superfamily. ABCC family. Conjugate transporter (TC 3.A.1.208) subfamily. | Solute carrier organic anion transporter family member 2A1; May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A; Belongs to the organo anion transporter (TC 2.A.60) family. | 0.595 |
AMH | SLCO2A1 | ENSP00000221496 | ENSP00000311291 | Muellerian-inhibiting factor; This glycoprotein, produced by the Sertoli cells of the testis, causes regression of the Muellerian duct. It is also able to inhibit the growth of tumors derived from tissues of Muellerian duct origin. | Solute carrier organic anion transporter family member 2A1; May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A; Belongs to the organo anion transporter (TC 2.A.60) family. | 0.591 |
HPGD | ABCC4 | ENSP00000296522 | ENSP00000494609 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Multidrug resistance-associated protein 4; May be an organic anion pump relevant to cellular detoxification; Belongs to the ABC transporter superfamily. ABCC family. Conjugate transporter (TC 3.A.1.208) subfamily. | 0.424 |
HPGD | PPARG | ENSP00000296522 | ENSP00000287820 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Peroxisome proliferator-activated receptor gamma; Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut ho [...] | 0.576 |
HPGD | PTGER2 | ENSP00000296522 | ENSP00000245457 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Prostaglandin E2 receptor EP2 subtype; Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the relaxing effect of this receptor on smooth muscle. | 0.461 |
HPGD | PTGER4 | ENSP00000296522 | ENSP00000302846 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Prostaglandin E2 receptor EP4 subtype; Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. Has a relaxing effect on smooth muscle. May play an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. | 0.637 |
HPGD | PTGES | ENSP00000296522 | ENSP00000342385 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Prostaglandin E synthase; Catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2); Belongs to the MAPEG family. | 0.723 |
HPGD | PTGFR | ENSP00000296522 | ENSP00000359793 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Prostaglandin F2-alpha receptor; Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and isoform 5 are proposed to be a receptor for prostamides including the synthetic analog bimatoprost. | 0.425 |
HPGD | SLCO2A1 | ENSP00000296522 | ENSP00000311291 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | Solute carrier organic anion transporter family member 2A1; May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A; Belongs to the organo anion transporter (TC 2.A.60) family. | 0.792 |
ITIH4 | MAN1A1 | ENSP00000266041 | ENSP00000357453 | 35 kDa inter-alpha-trypsin inhibitor heavy chain H4; Type II acute-phase protein (APP) involved in inflammatory responses to trauma. May also play a role in liver development or regeneration. | Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA; Involved in the maturation of Asn-linked oligosaccharides. Progressively trim alpha-1,2-linked mannose residues from Man(9)GlcNAc(2) to produce Man(5)GlcNAc(2); Belongs to the glycosyl hydrolase 47 family. | 0.613 |
ITIH4 | SLCO2A1 | ENSP00000266041 | ENSP00000311291 | 35 kDa inter-alpha-trypsin inhibitor heavy chain H4; Type II acute-phase protein (APP) involved in inflammatory responses to trauma. May also play a role in liver development or regeneration. | Solute carrier organic anion transporter family member 2A1; May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A; Belongs to the organo anion transporter (TC 2.A.60) family. | 0.877 |
MAN1A1 | ITIH4 | ENSP00000357453 | ENSP00000266041 | Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA; Involved in the maturation of Asn-linked oligosaccharides. Progressively trim alpha-1,2-linked mannose residues from Man(9)GlcNAc(2) to produce Man(5)GlcNAc(2); Belongs to the glycosyl hydrolase 47 family. | 35 kDa inter-alpha-trypsin inhibitor heavy chain H4; Type II acute-phase protein (APP) involved in inflammatory responses to trauma. May also play a role in liver development or regeneration. | 0.613 |
MAN1A1 | SLCO2A1 | ENSP00000357453 | ENSP00000311291 | Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA; Involved in the maturation of Asn-linked oligosaccharides. Progressively trim alpha-1,2-linked mannose residues from Man(9)GlcNAc(2) to produce Man(5)GlcNAc(2); Belongs to the glycosyl hydrolase 47 family. | Solute carrier organic anion transporter family member 2A1; May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A; Belongs to the organo anion transporter (TC 2.A.60) family. | 0.598 |
PPARG | HPGD | ENSP00000287820 | ENSP00000296522 | Peroxisome proliferator-activated receptor gamma; Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut ho [...] | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | 0.576 |
PPARG | PTGES | ENSP00000287820 | ENSP00000342385 | Peroxisome proliferator-activated receptor gamma; Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut ho [...] | Prostaglandin E synthase; Catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2); Belongs to the MAPEG family. | 0.443 |
PPARG | SLCO2A1 | ENSP00000287820 | ENSP00000311291 | Peroxisome proliferator-activated receptor gamma; Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut ho [...] | Solute carrier organic anion transporter family member 2A1; May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A; Belongs to the organo anion transporter (TC 2.A.60) family. | 0.478 |
PTGER2 | HPGD | ENSP00000245457 | ENSP00000296522 | Prostaglandin E2 receptor EP2 subtype; Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the relaxing effect of this receptor on smooth muscle. | 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. | 0.461 |
PTGER2 | PTGER4 | ENSP00000245457 | ENSP00000302846 | Prostaglandin E2 receptor EP2 subtype; Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the relaxing effect of this receptor on smooth muscle. | Prostaglandin E2 receptor EP4 subtype; Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. Has a relaxing effect on smooth muscle. May play an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. | 0.962 |
PTGER2 | PTGES | ENSP00000245457 | ENSP00000342385 | Prostaglandin E2 receptor EP2 subtype; Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the relaxing effect of this receptor on smooth muscle. | Prostaglandin E synthase; Catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2); Belongs to the MAPEG family. | 0.737 |